H. Jack

BeaconMedIC
My videos
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
00:13:27

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.

1,200 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
00:08:57

What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
925 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
00:09:58

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
689 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
00:09:53

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
614 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
00:06:38

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
549 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
00:09:41

The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
463 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
00:04:12

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
424 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
00:08:03

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
222 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
00:07:21

Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
257 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
00:07:18

IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
331 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
00:09:08

"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
332 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
00:15:36

Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
342 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
00:03:39

TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
325 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
00:01:34

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
247 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
00:02:46

What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
256 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
00:03:02

New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
179 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
00:02:02

Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
197 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
00:01:08

Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
106 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
00:02:17

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
205 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
00:02:18

Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
97 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
00:03:18

Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
77 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
00:02:06

Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
57 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
00:04:37

Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
76 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
00:02:58

Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
99 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
00:01:57

Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
101 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login